Eri Matsuki

694 citations

41 papers · 492 indexed · h-index 11

Impact in

Hematology top 5%
- Chronic Myeloid Leukemia Treatments
Genetics top 10%
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Hematology 22
- Chronic Myeloid Leukemia Treatments 14
Genetics 17
- Chronic Lymphocytic Leukemia Research 11
- Myeloproliferative Neoplasms: Diagnosis and Treatment 4

Co-authors: Anas Younes (5 shared papers)Renier J. Brentjens (1 shared paper)Connie Lee Batlevi (1 shared paper)Shinichiro Okamoto (22 shared papers)Kenji Yokoyama (8 shared papers)Takayuki Shimizu (10 shared papers)Masatoshi Sakurai (11 shared papers)Yoshitaka Miyakawa (5 shared papers)
Journals: Blood (10 papers)International Journal of Hematology (4 papers)Blood Cancer Journal (2 papers)Cancer (1 paper)Clinical Cancer Research (1 paper)
Partner nations: Japan United States United Kingdom

In The Last Decade

Eri Matsuki

39 papers receiving 480 citations

Peers

Countries citing papers authored by Eri Matsuki

Since Specialization

Citations

This map shows the geographic impact of Eri Matsuki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eri Matsuki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eri Matsuki more than expected).

Fields of papers citing papers by Eri Matsuki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eri Matsuki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eri Matsuki. The network helps show where Eri Matsuki may publish in the future.

Co-authors

The 25 scholars most cited alongside Eri Matsuki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eri Matsuki Line = papers co-authored together Eri Matsuki links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Novel immunotherapies in lymphoid malignancies Nature Reviews Clinical Oncology ·Connie Lee Batlevi, Eri Matsuki, Renier J. Brentjens, Anas Younes	2015	184
2	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma Current Treatment Options in Oncology ·Eri Matsuki, Anas Younes	2016	51
3	Lymphomagenesis in Hodgkin lymphoma Seminars in Cancer Biology ·Eri Matsuki, Anas Younes	2015	26
4	Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia International Journal of Hematology ·Takashi Kumagai, Eri Matsuki, Koiti Inokuchi, Kazuteru Ohashi, Atsushi Shinagawa, Jin Takeuchi, Chikashi Yoshida, Shinichiro Okamoto, Hisashi Wakita, Yasuji Kozai, Yukari Shirasugi, Shin Fujisawa, Osamu Iwase, Shingo Yano, Kaichi Nishiwaki, Koji Oba, Junichi Sakamoto, Hisashi Sakamaki	2013	19
5	Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia International Journal of Hematology ·Masatoshi Sakurai, Taku Kikuchi, Daiki Karigane, Hidenori Kasahara, Eri Matsuki, Risa Hashida, Yusuke Yamane, Ryohei Abe, Yuya Koda, Takaaki Toyama, Jun Kato, Takayuki Shimizu, Yuta Yokoyama, Sayo Suzuki, Tomonori Nakamura, Shinichiro Okamoto, Takehiko Mori	2019	17
6	Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab Applied immunohistochemistry & molecular morphology ·Eri Matsuki, Olga L. Bohn, Siraj M. El Jamal, Janine Pichardo, Andrew D. Zelenetz, Anas Younes, Julie Teruya‐Feldstein	2018	16
7	Recent Advances of Acute Kidney Injury in Hematopoietic Cell Transplantation Frontiers in Immunology ·Masahiro Miyata, Kazunobu Ichikawa, Eri Matsuki, Masafumi Watanabe, Daniel Peltier, Tomomi Toubai	2022	15
8	Successful Treatment of Adult Onset Langerhans Cell Histiocytosis with Multi-Drug Combination Therapy Internal Medicine ·Eri Matsuki, Yuiko Tsukada, Aya Nakaya, Kenji Yokoyama, Shinichiro Okamoto	2011	14
9	Adult Sporadic Burkitt Lymphoma of the Oral Cavity: A Case Report and Literature Review Journal of Oral and Maxillofacial Surgery ·Kentaro Kikuchi, Harumi Inoue, Yuji Miyazaki, Fumio Ide, Eri Matsuki, Hisao Shigematu, Shinichiro Okamoto, Hideaki Sakashita, Kaoru Kusama	2012	12
10	CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients Blood Cancer Journal ·Maiko Matsushita, Kyoko Ozawa, Takaya Suzuki, Masaru Nakamura, Naomi Nakano, Saori Kanchi, Daiju Ichikawa, Eri Matsuki, Masatoshi Sakurai, Daiki Karigane, Hidenori Kasahara, Nobuo Tsukamoto, Takayuki Shimizu, Takehiko Mori, Hideaki Nakajima, Shinichiro Okamoto, Yutaka Kawakami, Yutaka Hattori	2017	12
11	Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib – an Updated Result of the Keio STIM Study. Blood ·Eri Matsuki, Yukako Ono, Koharu Tonegawa, Masatoshi Sakurai, Hiroyoshi Kunimoto, Jo Ishizawa, Norisato Hashimoto, Takayuki Shimizu, Akiko Yamane, Maiko Matsushita, Kenji Yokoyama, Shinichiro Okamoto	2012	12
12	Identification of Loss of p16 Expression and Upregulation of MDR-1 as Genetic Events Resulting from Two Novel Chromosomal Translocations Found in a Plasmablastic Lymphoma of the Uterus Clinical Cancer Research ·Eri Matsuki, Yoshitaka Miyakawa, Shuichi Asakawa, Yuiko Tsukada, Taketo Yamada, Kenji Yokoyama, Jun Kudoh, Yasuo Ikeda, Shinichiro Okamoto	2011	10
13	A novel factor XII mutation, FXII R84P, causing factor XII deficiency in a patient with hereditary spastic paraplegia Blood Coagulation & Fibrinolysis ·Eri Matsuki, Yoshitaka Miyakawa, Shinichiro Okamoto	2011	9
14	Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high‐performance liquid chromatography–Photodiode array detection Journal of Clinical Laboratory Analysis ·Yuta Yokoyama, Eiji Nozawa, Miho Morita, Emi Ishikawa, Takehiko Mori, Masatoshi Sakurai, Taku Kikuchi, Eri Matsuki, Rie Yamazaki, Keisuke Kataoka, Aya Jibiki, Hitoshi Kawazoe, Sayo Suzuki, Tomonori Nakamura	2022	9
15	Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase Journal of Clinical and Experimental Hematopathology ·Koiti Inokuchi, Takashi Kumagai, Eri Matsuki, Kazuteru Ohashi, Atsushi Shinagawa, Yoshihiro Hatta, Jin Takeuchi, Chikashi Yoshida, Hisashi Wakita, Yasuji Kozai, Yukari Shirasugi, Shin Fujisawa, Osamu Iwase, Shingo Yano, Shinichiro Okamoto, Koji Oba, Junichi Sakamoto, Hisashi Sakamaki	2014	8
16	Second Attempt to Discontinue TKI in CML Patients Who Have Sustained CMR for over 2 Years Is Rarely Successful Even with the Use of Second Generation TKIs Blood ·Eri Matsuki, Masatoshi Sakurai, Daiki Karigane, Hidenori Kasahara, Taku Kikuchi, Takayuki Shimizu, Kenji Yokoyama, Takehiko Mori, Shinichiro Okamoto	2016	8
17	An Empirical Study of the Prescription Pattern of Drugs for Hematological Malignancies in Japan from 2010–2014 Biological and Pharmaceutical Bulletin ·Shoyo Shibata, Yusuke Wayama, Ai Tsuyuki, Maiko Matsushita, Kōji Chiba, Eri Matsuki, Shinichiro Okamoto, Takeshi Suzuki	2017	8
18	Discontinuation of Imatinib in Patients with CML and Sustained Complete Molecular Response (CMR) for Over 2 Years in the Japanese Population – An Interim Analysis of KEIO STIM Study, Blood ·Eri Matsuki, Yukako Ono, Masatoshi Sakurai, Hiroyoshi Kunimoto, Jo Ishizawa, Takayuki Shimizu, Akiko Yamane, Maiko Matsushita, Kenji Yokoyama, Shinichiro Okamoto	2011	7
19	Unfavorable outcome of chronic myelogenous leukemia in adolescent and young adults treated with tyrosine kinase inhibitors International Journal of Hematology ·Masatoshi Sakurai, Takehiko Mori, Daiki Karigane, Keiichi Tozawa, Eri Matsuki, Takayuki Shimizu, Kenji Yokoyama, Hideaki Nakajima, Yoshinobu Kanda, Shinichiro Okamoto	2015	7
20	Eosinophilic annular erythema showing eosinophil cytolytic ETosis successfully treated with benralizumab Asia Pacific Allergy ·Katsunori Masaki, Shigeharu Ueki, Keiji Tanese, Genta Nagao, Sho Kanzaki, Eri Matsuki, H. Irie, Hiroki Kabata, Jun Miyata, Ichiro Kawada, Koichi Fukunaga	2021	6

About Eri Matsuki

Eri Matsuki is a scholar working on Hematology, Genetics, Oncology, Rheumatology and Pathology and Forensic Medicine, having authored 41 papers that have together received 492 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (14 papers), Chronic Lymphocytic Leukemia Research (11 papers), Eosinophilic Disorders and Syndromes (9 papers), Immune Cell Function and Interaction (7 papers), Lymphoma Diagnosis and Treatment (7 papers), Acute Lymphoblastic Leukemia research (5 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). The work is most often cited by research in Hematology (153 citations), Genetics (127 citations), Oncology (249 citations), Pathology and Forensic Medicine (134 citations) and Immunology (132 citations). Eri Matsuki has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Anas Younes, Renier J. Brentjens, Connie Lee Batlevi, Shinichiro Okamoto, Kenji Yokoyama, Takayuki Shimizu, Masatoshi Sakurai, Yoshitaka Miyakawa, Tomomi Toubai and Daniel Peltier. Their work appears in journals such as Blood, International Journal of Hematology, Blood Cancer Journal, Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact